New study aims to uncover nerve side effects of cancer drug
NCT ID NCT07390617
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the drug enfortumab vedotin affects nerves in people with advanced or muscle-invasive bladder cancer. Researchers will use nerve tests and patient surveys to track changes over 9-15 weeks. The goal is to better understand and potentially reduce nerve damage caused by the treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- enfortumab vedotin
- What this could lead to
- If successful, this study could help doctors better predict or manage nerve damage from enfortumab vedotin, improving quality of life for patients.
- What could go wrong
- This is a small, early observational study with only 50 participants. It does not test a new treatment, so it may not lead to direct changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
RECRUITINGRockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers